Small Cell Lung Carcinoma
"Small Cell Lung Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
| Descriptor ID |
D055752
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.624 C08.381.540.140.750 C08.785.520.100.220.750
|
| Concept/Terms |
Small Cell Lung Carcinoma- Small Cell Lung Carcinoma
- Small Cell Lung Cancer
- Oat Cell Lung Cancer
- Small Cell Cancer Of The Lung
- Carcinoma, Small Cell Lung
- Oat Cell Carcinoma of Lung
|
Below are MeSH descriptors whose meaning is more general than "Small Cell Lung Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Small Cell Lung Carcinoma".
This graph shows the total number of publications written about "Small Cell Lung Carcinoma" by people in this website by year, and whether "Small Cell Lung Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 1 | 5 |
| 2010 | 5 | 1 | 6 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 0 | 3 |
| 2013 | 6 | 0 | 6 |
| 2014 | 1 | 0 | 1 |
| 2015 | 5 | 1 | 6 |
| 2016 | 4 | 1 | 5 |
| 2017 | 3 | 1 | 4 |
| 2018 | 6 | 0 | 6 |
| 2019 | 1 | 0 | 1 |
| 2020 | 5 | 0 | 5 |
| 2021 | 6 | 0 | 6 |
| 2022 | 6 | 0 | 6 |
| 2023 | 7 | 0 | 7 |
| 2024 | 9 | 1 | 10 |
| 2025 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Small Cell Lung Carcinoma" by people in Profiles.
-
Association between ultra-processed food consumption and lung cancer risk: a population-based cohort study. Thorax. 2025 Oct 15; 80(11):810-818.
-
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024. Cancer. 2025 Sep 01; 131(17):e70060.
-
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025 Dec; 26(8):626-641.
-
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results. Clin Lung Cancer. 2025 Nov; 26(7):541-551.
-
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May; 21(12):1511-1523.
-
ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy. J Am Coll Radiol. 2025 May; 22(5S):S319-S342.
-
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer. 2025 Feb 01; 131(3):e35738.
-
Chromothripsis-Mediated Small Cell Lung Carcinoma. Cancer Discov. 2025 Jan 13; 15(1):83-104.
-
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 2025 Jan 01; 131(1):e35663.
-
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5042-5052.